Phio Pharmaceuticals Corp (NASDAQ:PHIO) Sees Large Decline in Short Interest

Phio Pharmaceuticals Corp (NASDAQ:PHIO) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totalling 587,600 shares, a drop of 18.3% from the June 30th total of 718,900 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 195,800 shares, the short-interest ratio is currently 3.0 days.

PHIO stock remained flat at $$0.35 during midday trading on Thursday. The company’s stock had a trading volume of 163,051 shares, compared to its average volume of 414,003. The firm’s 50-day moving average is $0.39. The company has a debt-to-equity ratio of 0.04, a quick ratio of 8.52 and a current ratio of 8.52. The firm has a market capitalization of $8.36 million, a PE ratio of -0.34 and a beta of 1.83. Phio Pharmaceuticals has a 12 month low of $0.27 and a 12 month high of $2.19.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). Analysts anticipate that Phio Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC lifted its holdings in Phio Pharmaceuticals by 148.9% in the 2nd quarter. Citadel Advisors LLC now owns 85,621 shares of the company’s stock valued at $33,000 after purchasing an additional 51,216 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Phio Pharmaceuticals by 39.8% in the 1st quarter. SG Americas Securities LLC now owns 228,825 shares of the company’s stock valued at $103,000 after purchasing an additional 65,095 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Phio Pharmaceuticals in the 1st quarter valued at $107,000. Institutional investors own 7.08% of the company’s stock.

Separately, ValuEngine upgraded Phio Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Recommended Story: Options Trading – Understanding Strike Price

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit